This included significant increases in full-length IFN-γ (23–166), as revealed by immunoreactivity against the N-terminal and C-terminal-1 antibodies, and significant increases in active IFN-γ in the SLE patients, as revealed by positive immunostaining of both anti–C-terminal antibodies. This evidence concerns the gene IFNG and systemic lupus erythematosus.